Posted by Michael Wonder on 25 Oct 2022
US FDA approves Tecvayli (teclistamab-cqyv), the first bispecific T-cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma
25 October 2022 - Tecvayli, an off the shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the US FDA approved Tecvayli (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.
